Assessment of chemotherapy on various biochemical markers in breast cancer patients

Márcia F.C.J. Paz, Antonio L. Gomes, Muhammad T. Islam, Shams Tabrez, Nasimudeen R. Jabir, Mohammad Z. Alam, Kátia C. Machado, Marcus V.O.B. de Alencar, Keylla C. Machado, Eunus S. Ali, Siddhartha K. Mishra, Leonardo F. Gomes, André Luiz Pinho Sobral, João M.C. e Sousa, Geane F. de Souza, Ana Amélia C. Melo-Cavalcante, Juliana da Silva

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Chemotherapy is a standard treatment method for the patients with locally advanced breast cancer. Lately, cyclophosphamide (CYP) and doxorubicin (DOX) are used as the major chemotherapeutic agents especially for the treatment of breast cancer. Till date, no serum biomarker has been able to provide an early diagnosis of breast cancer. This study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX. Blood samples were collected from the patients at the each treatment stages mentioned above. These samples were assessed for interleukin 6 (IL-6), interleukin 10 (IL-10), lactate dehydrogenase (LDH), creatine kinase (CK), creatinine, hemoglobin (Hb), leukocyte, platelet and Na+/K+-ATPase levels either by ELISA or colorimetric methods. The results suggest a significant increase in IL-6 level at all the stages in BCP as compared to control group. On the other hand, IL-10, CK and Na+/K+-ATPase levels were found to be significantly declined during all the stages. Moreover, the majority of hematological parameters remained unchanged throughout the treatment period with the exception of creatinine and Hb which showed slight modulation in their level at different stages. Based on the results, we conclude that breast cancer and co-treatment with CYP and DOX, interfere arious biological markers, thereby, showing the physiological imbalance.

Original languageEnglish
Pages (from-to)2923-2928
Number of pages6
JournalJournal of Cellular Biochemistry
Issue number3
StatePublished - Mar 2018

Bibliographical note

Publisher Copyright:
© 2017 Wiley Periodicals, Inc.


  • breast cancer
  • chemotherapy
  • cyclophosphamide
  • cytokines
  • doxorubicin

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Assessment of chemotherapy on various biochemical markers in breast cancer patients'. Together they form a unique fingerprint.

Cite this